In Wake Of Heparin Deaths, FDA Set To Launch Pilot Project Aimed At Preventing Imports Of Adulterated Drugs
This article was originally published in PharmAsia News
Executive Summary
BEIJING - One year after adulterated heparin sourced from China began triggering scores of adverse reactions and deaths in U.S. patients, U.S. FDA is preparing to launch a voluntary pilot program aimed at helping prevent contaminated drugs from entering the country
You may also be interested in...
FDA May Require Drug Importers To Verify Product Quality
Public meeting will solicit stakeholder comments on how FDASIA-mandated import regulations should be implemented as the expedited entry program reemerges.
IOM Pushes For FDA Collaboration With Foreign Regulators
In a report on how FDA, industry and other stakeholders can strengthen food and drug regulatory systems abroad, the Institute of Medicine recommends the agency provide incentives for foreign regulators to meet U.S. standards and facilitate training and for the government to help hold importers liable.
IOM Pushes For FDA Collaboration With Foreign Regulators
In a report on how FDA, industry and other stakeholders can strengthen food and drug regulatory systems abroad, the Institute of Medicine recommends the agency provide incentives for foreign regulators to meet U.S. standards and facilitate training and for the government to help hold importers liable.